Paclitaxel nanopolymer - Samyang Biopharmaceuticals Corporation
Alternative Names: Paclitaxel PNPLatest Information Update: 09 Apr 2025
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Apr 2025 Discontinued - Preclinical for Cancer in South Korea (unspecified route) (Samyang Biopharmaceuticals pipeline; April 2025)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea
- 01 Aug 2012 Nanopolymer paclitaxel is available for licensing worldwide as of 01 Aug 2012. http://www.samyangbiopharm.com